This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

This study has been completed.
Information provided by:
Biogen Identifier:
First received: October 10, 2008
Last updated: September 12, 2013
Last verified: May 2011
Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.

Condition Intervention Phase
Rheumatoid Arthritis Drug: BIIB023 Other: Placebo (sterile normal saline) Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • Determine the safety and tolerability of single doses of BIIB023 administered intravenously (IV) to subjects with RA. [ Time Frame: Baseline through Day 70 ]

Secondary Outcome Measures:
  • • Estimate the pharmacokinetic (PK) parameters of single doses of BIIB023 administered IV to subjects with RA • Evaluate potential markers of pharmacodynamic (PD) action of BIIB023 and its biological effects [ Time Frame: Day -1, 0 (at several timepoints), 1, 2, 7, 14, 21, 28, 42, 56 and Day 70 ]

Enrollment: 53
Study Start Date: October 2008
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: BIIB023
Single IV doses of BIIB023 in dose-escalating cohorts
Other Name: Human glycosylated IgG1 monoclonal antibody
Placebo Comparator: 2 Other: Placebo (sterile normal saline)
Single IV dose of Placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of adult onset RA (functional class I-III) for at least 6 months
  • Must have been treated with and be tolerating Methotrexate (5-25 mg/week) for 3 months, at a stable dose for at least 4 weeks
  • Must have at least 4 swollen and tender joints due to rheumatoid arthritis

Exclusion Criteria:

  • History of recurrent infections requiring antibiotic treatment within 12 months
  • Serious local infection or systemic infection within 3 months
  • Suffering from rheumatic or autoimmune disease other than RA
  • History of cancer, heart failure, kidney disease, liver disease, HIV infection, tuberculosis or other serious illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00771329

United States, Alabama
Research Site
Anniston, Alabama, United States
United States, California
Research Centre
Palm Desert, California, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Research Centre
Duncansville, Pennsylvania, United States
Russian Federation
Research Centre
Moscow, Russian Federation
Research Centre
Yaroslavl, Russian Federation
Sponsors and Collaborators
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Medical Director, Biogen Idec Identifier: NCT00771329     History of Changes
Other Study ID Numbers: 211RA101
Study First Received: October 10, 2008
Last Updated: September 12, 2013

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on August 18, 2017